Literature DB >> 3947041

Alternative single anticonvulsant drug therapy for refractory epilepsy.

D Schmidt, K Richter.   

Abstract

Fifty-nine patients with chronic generalized tonic-clonic or partial seizures refractory to the maximally tolerated daily dosage of single-drug therapy with carbamazepine, phenytoin, phenobarbital, or primidone subsequently received single-drug therapy with another one of these primary anticonvulsant drugs. Alternative single-drug therapy resulted in complete seizure control or more than 75% seizure reduction for 18 patients (31%). Side effects disappeared in 16 patients (27%). Patients with a good therapeutic response often had epilepsy of recent onset. Alternative single-drug therapy is beneficial for chronic refractory epilepsy and should be considered before a second drug is permanently added.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947041     DOI: 10.1002/ana.410190118

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

Review 1.  Place of polytherapy in the early treatment of epilepsy.

Authors:  Charles L P Deckers
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Lamotrigine. A review of its use in childhood epilepsy.

Authors:  C R Culy; K L Goa
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

Review 3.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  The new anticonvulsant drugs. Implications for avoidance of adverse effects.

Authors:  D Schmidt; G Krämer
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

Review 5.  Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 6.  Modern treatment strategies for patients with epilepsy: a review.

Authors:  J S Duncan
Journal:  J R Soc Med       Date:  1991-03       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.